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Abstract
Background:  In the past three years, many large employers in South Africa have announced
publicly their intention of making antiretroviral treatment (ART) available to employees.
Reports of the scope and success of these programs have been mostly anecdotal.  This study
surveyed the largest private sector employers in South Africa to determine the proportion of
employees with access to ART through employer-sponsored HIV/AIDS treatment programs.
Methods:  All 64 private sector and parastatal employers in South Africa with more than 6,000
employees were identified and contacted.  Those that agreed to participate were interviewed by
telephone using a structured questionnaire.
Results:  52 companies agreed to participate.  Among these companies, 63% of employees had
access to employer-sponsored care and treatment for HIV/AIDS.  Access varied widely by
sector, however.  Approximately 27% of suspected HIV-positive employees were enrolled in
HIV/AIDS disease management programs, or 4.4% of the workforce overall.  Fewer than 4,000
employees in the entire sample were receiving antiretroviral therapy.  In-house (employer)
disease management programs and independent disease management programs achieved higher
uptake of services than did medical aid schemes.
Conclusions:  Publicity by large employers about their treatment programs should be interpreted
cautiously.  While there is a high level of access to treatment, uptake of services is low and only
a small fraction of employees medically eligible for antiretroviral therapy are receiving it.
Keywords:  HIV/AIDS, South Africa, Private Sector,Antiretroviral Therapy, Disease
Management Program.
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1.  Introduction
In the past three years, many of South Africa's largest and most prominent private sector
companies have announced and launched workplace HIV/AIDS treatment programs.  These
announcements have frequently been accompanied by much fanfare on the part of the companies
and high praise in the media (see, for example, Bolin 2005;Venter 2005).  Evidence about the
success these companies have had in enrolling employees in their care and treatment programs
and putting them onto antiretroviral therapy (ART), however, has been fragmented and
anecdotal.  Considering the varied motivations for providing care and treatment—in some cases
purely financial, in others at least partly humanitarian—it is important to understand the extent
and success of these programs, which have the potential to lessen the burden on the public sector
of HIV/AIDS care and reserve more “slots” in the national AIDS treatment program for those
who cannot afford private care.
The manner in which South African companies make HIV/AIDS care and treatment available to
employees can be categorized into four models (Connelly and Rosen 2004):
• Model 1:  Employer Provider.  The employer internally finances and delivers treatment and
care for HIV-positive employees.  The company may use either a “closed” medical scheme,1
company clinic facilities, or a combination of the two.
• Model 2:  Medical Scheme.  Employers subsidise medical aid scheme premiums for
employees who choose to make the co-payment.2  Most medical aid schemes contract with a
disease management program (DMP) to handle the treatment and care of HIV-positive
members.  Medical aid scheme members must typically enrol separately in the DMP (i.e.
enrolment is not automatic).
• Model 3: Independent Disease Management Program (DMP). A specialized HIV/AIDS
disease management company is contracted by an employer to manage the costs and
treatment of HIV-positive employees, independent of whatever medical aid scheme may be
available.
• Model 4: Clinic Provider.  External treatment and care provider (clinic) is contracted by the
employer to provide HIV-related services either at the workplace or at an outside clinic.
Each of these models of care and treatment involves some level of financial cost to the employer.
How effective the different models of care and treatment have been in enrolling HIV-positive
members and providing high quality care and treatment has rarely been communicated by
providers or purchasers of the services.  The most revealing information has come from Anglo
American, which has developed an extensive program following the “Employer Provider”
approach (Model 1).  After more than two and a half years of operation, about 22 percent of
those who are believed to be HIV-positive have enrolled in the program and just under 3,000
started on ART.  Results in some divisions of the company have been extremely
encouraging—nearly 100 percent uptake of both DMP and ART in one mine, for example—but
                                                      
1 Closed medical schemes are usually only available to employees of the company and their dependents.
2 Medical aid schemes are similar to health insurance providers in the U.S.
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patient attrition has also been high.  Nearly 30 percent of those started on ART are no longer
being treated.  Despite low overall enrollment in the DMP and high attrition from ART,
however, it is likely that Anglo American has among the most successful private sector programs
in the country (Brink 2005; Kahn 2005).
In the second half of 2004, we conducted a brief telephone survey of the largest private sector
employers in South Africa to determine what proportion of employees have access to HIV/AIDS
care and treatment, including ART; how many employees are enrolled in disease management
programs; how many are receiving ART; and which approach to the financing and delivery of
care is proving most successful at reaching eligible employees.  We also asked interviewees the
results of any estimates carried out for or by the company of the prevalence of HIV infection
amongst employees.
Two recent developments in South Africa are important to understanding the findings that
follow.  First, in 2004 South Africa began providing ART through public hospitals and clinics.
As of mid 2005, some 45,000 patients were receiving care at public “ARV rollout” sites (TAC
and ALP 2005).  Although universal access to ART is the long-term goal of the national
program, scaling up services will take many years, and currently fewer than 10 percent of
medically eligible patients are receiving ART in the public and private sectors (Rosen et al.
2005).  Although many employers will rely on the public sector to take care of HIV-positive
workers, it is not safe to assume that employees will have ready access to treatment at public
clinics for many years to come.  The second relevant development occurred in 2005, when
antiretroviral therapy was added to the “prescribed minimum benefits” that medical aid schemes
are required to provide.  Employees who belong to medical aid schemes can therefore be
assumed to have access to ART.
1. Methods
All private and parastatal companies with 6,000 or more permanent employees were included in
our population.  Employment figures were provided by Matrix Marketing, a private sector
database consulting company.  Structured interviews were conducted by telephone between
September and November 2004.  At each company, we interviewed the HIV/AIDS Program
Manager, Human Resources Manager, or other individual with knowledge of the current status
of the program.
Interviews included questions about the size of the company’s labor force in South Africa,
estimated prevalence of HIV in the workforce, commencement date of the HIV/AIDS disease
management or treatment program, number of employees enrolled in the program, and number
of employees currently receiving ART.  Interviewees were also asked about the manner in which
HIV disease management services and ART are being delivered and financed.
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2. Results
a.  Access to AIDS care and treatment
Of the 64 companies in our study population, 52 participated in the study.  Ten companies were
unresponsive to repeated telephone and e-mail requests for information and two companies
refused to participate.  Characteristics of the participating companies are presented in Table 1.
Because of the workforce size requirement for the study population (at least 6,000 employees),
some of the South African firms whose HIV/AIDS programs have received the most publicity,
such as Daimler-Chrysler South Africa, are not included in the sample (Planting 2005).
Table 1:  Characteristics of surveyed companies
Industry No. (%) of surveyed
companies
Total no. employees Average no.
employees
Retail 14 (27%) 157,100 11,221
Mining 12 (23%) 313,915 26,160
Manufacturing 7 (13%) 64,200 9,171
Financial services 6 (12%) 133,434 22,239
Community, social and
personal services (CSPS)
4 (8%) 78,400
19,600
Transport, storage, and
communication (TSC)
4 (8%) 145,000
36,250
Construction 3 (6%) 31,500 10,500
Agriculture 2 (4%) 18,200 9,100
Totals 52 (100%) 941,749 18,111
All of the surveyed companies offered to subsidize medical aid membership for some or all of
their employees, typically paying 50 percent of the premium for employees and dependents.  For
medical aid scheme members, ART is a standard benefit.  Only a minority of all employees,
however, actually belong to a medical aid.  Membership is optional and typically concentrated
among managers and supervisors, who also are least likely to be HIV-positive.  Few unskilled
workers opt to join, presumably because the 50 percent co-payment is very high for a low-wage
worker.  Since all of the companies have at least some employees on medical aid, none of them
can be said to provide no access to ART.  Since medical aid membership is typically very low
among the majority of the workforce in the skilled and unskilled job bands, however, we will
consider a company to have an AIDS treatment program only if all of its employees have access
to ART, regardless of which model or models are used.
Roughly half of the companies surveyed (n = 25) make ART available to all permanent
employees.  Coverage of HIV/AIDS treatment access varied by industry, as shown in Table 2.
All financial services companies and three quarters of mining companies make ART available to
all employees, but just 21 percent of retail firms and none of the construction or community,
social and personal services companies do. 
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Table 2: Number and percentage of employees with access to ART, by industry
Industry No. of
companies
surveyed
No. making ART
available to all
employees
% making ART
available to all
employees
No. employees
with access†
%  of
employees with
access
Retail 14 3 21% 83,939 37%
Mining 12 8 75% 273,919 90%
Manufacturing 7 5 71% 55,600 80%
Financial services 6 6 100% 133,434 100%
CSPS 4 0 0% 8,760 13%
TSC 4 2 50% 130,660 74%
Construction 3 0 0% 8,080 51%
Agriculture* 2 1 50% 2,875 59%
Totals 52 25 48% 697,267 63%
*Information from one of the agriculture companies was only available for one unit.
†From all companies, including those for which only some employees have access.
On average, 63 percent of permanent employees of surveyed firms have access to HIV/AIDS
care and treatment financed by their employer.  This figure is driven largely by widespread
access in the mining and financial industries.
b.  HIV prevalence
In order to analyse the enrolment rates of HIV-positive employees in HIV disease management
programs and on ART, we asked if the respondent’s company had estimated the prevalence of
HIV amongst its employees.  Thirty-four of the surveyed companies had made such estimates,
and 28 were willing to disclose the results to our interviewers.  The average prevalence of HIV
infection at the 28 reporting companies was 15.7 percent.  In the mining sector, 11 of the 12
participating companies provided prevalence estimates; the average prevalence was 19.2 percent.
For retail/wholesale and manufacturing, 5 companies in each sector provided estimates; the
average infection levels were 11.7 percent and 10.7 percent, respectively.  Estimates of
prevalence were provided by only a few companies in the financial, telecommunications,
agriculture, and community, social and personal services sectors.
c.  Utilization of ART benefits
Table 3 provides results on treatment program monitoring, enrolment, and ART uptake.
Monitoring by companies of utilization of their AIDS treatment benefit varied.  Approximately
half the companies in our survey (n=25), with a combined workforce of roughly 600,000, could
tell us the number of employees enrolled in the HIV disease management program and/or the
number receiving ART.  At these companies, 26,010 employees, or 4.4 percent of the total, were
enrolled in HIV/AIDS disease management programs at the time of the survey.  Approximately
3,908 employees, or 0.7 percent of the total, were currently receiving ART.   
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Table 3:  Utilization of treatment and care, end 2004
Industry Number of
companies
reporting uptake
Number of
employees
Number of
employees in
HIV DMP
% of
employees in
HIV DMP
Number of
employees
on ART
% of  all
employees
on ART
Retail 3 44,900 70 0.2% 52 0.1%
Mining 9 275,300 24,066 8.7% 2,954 1.1%
Manufacturing 4 36,700
Insufficient
data* n.a. 518 1.4%
Financial serv. 4 112,500 910† 0.8% 330† 0.3%
CSPS 0 n.a. n.a. n.a. n.a. n.a.
TSC 3 119,000 824 0.7% 6 0.0%
Construction 0 n.a. n.a. n.a. n.a. n.a.
Agriculture 2 8,475 140 1.7% 48 0.6%
Total 25 596,875 26,010 4.4% 3,908 0.7%
*Two of the manufacturing firms did not provide information about DMPs.  One does not have an HIV DMP and the other does not know how
many employees are enrolled.
†Utilization figures for the four financial companies include dependents.
d.  Treatment program models
We distributed the surveyed companies among the three models of treatment provision based on
the characteristics of their treatment programs.  Looking only at those companies that make
treatment available to all employees, 10 have adopted the independent DMP model (Model 3), 9
the employer provider model (Model 1), and 6 the medical scheme model (Model 2).  No
companies surveyed purchase services from a clinic provider (Model 4).  As previously
mentioned, all the remaining companies (n=27) have at least some employees with access to
treatment through their medical aid scheme, but the proportion of employees covered in these
firms is low, averaging 32 percent.
The breakdown of model choice by sector is shown in Table 4.  Most of the companies with an
internal program (Model 1) are in the mining sector, while most of those in which all employees
are covered by medical aid (Model 2) are in the financial services sector.
Table 4: HIV/AIDS treatment model utilised by surveyed companies
Industry No. of
companies
surveyed
Model 1:
Employer
Provider
Model 2:
Medical Scheme
(All employees
covered)
Model 3:
Independent
DMP
No program:
partial coverage
through medical
scheme
Retail 14 1 1 1 11
Mining 12 7 0 1 4
Manufacturing 7 1 0 4 2
Financial serv. 6 0 4 2 0
CSPS 4 0 0 0 4
TSC 4 0 1 1 2
Construction 3 0 0 0 3
Agriculture 2 0 0 1 1
Total 52 9 6 10 27
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There are significant differences in monitoring, access to, and utilization of HIV/AIDS treatment
and care benefits between companies using different models, as shown in Table 5.  All
companies offering HIV/AIDS treatment and care internally (employer provider) or through an
independent DMP had made estimates of HIV prevalence among employees and knew enrolment
rates into DMPs and onto ART.  Of the 33 companies relying on medical schemes for HIV/AIDS
treatment and care, 12 knew utilization rates.  Four of these companies refused to reveal the
information to the study team, however.
To estimate uptake ratios for disease management programs and ART, we required an estimate
of HIV prevalence, the number of employees enrolled in the DMP, and the number currently on
ART.  We obtained all three variables from 23 companies.  Overall, 27 percent of suspected
HIV-positive employees are enrolled in disease management programs and 3.8 percent are
receiving ART.  Companies making treatment services available internally (Model 1) reported
that 44 percent of HIV-positive employees were enrolled in DMPs, more than three times higher
than the independent DMP or medical scheme models.  This may reflect the greater success of
Model 1 companies in promoting HIV testing among employees.  Many companies with internal
programs also have longstanding “HIV wellness programs” that predate the introduction of ART
by several years.  Companies using independent DMPs, in contrast, reported the highest rate of
ART uptake: 6.8 percent, versus 5.1 percent and 2.7 percent for companies using the employer
provider and the medical scheme model, respectively.
Table 5: Coverage of HIV/AIDS treatment and care benefits by model, end 2004
Variable Model #1
Employer
Provider
Model #2*
Medical Scheme
DMP (all employees
covered)
Model #3
Independent
DMP
No program:
partial coverage
through medical
scheme
Totals
Number and proportion of
companies reporting HIV
prevalence, DMP
enrollment, and ART rates
9 (100%) 5 (50%) 6 (60%) 3 (13%) 23 (44%)
Number of employees at
companies reporting HIV
prevalence, DMP
enrollment, and ART rates
273,424 249,545 97,474 30,800 651,243
Estimated HIV prevalence 19.4% 4.9% 9.8% 14.3% 15.2%
(weighted)
Inferred number of HIV-
positive employees
53,044 12,228 9,552 4,404 98,989
Number of HIV–positive
employees enrolled in
DMP
23,332 1,690 1,136 376 26,534
Proportion of estimated
HIV-positive employees
enrolled in DMP
44.0% 13.8% 11.9% 8.5% 26.8%
Number of HIV-positive
employees receiving ART
2,719 330 650 73 3,772
Proportion of estimated
HIV-positive employees
receiving ART
5.1% 2.7% 6.8% 1.7% 3.8%
*Utilization figures for four of the Model #2 companies include dependents.
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3. Discussion
Most of the information available to date about HIV/AIDS treatment and care programs at very
large companies in South Africa has come from a small number of high-profile companies
communicating the success of their efforts.  Few details have been released on the extent of
access to and utilization of HIV/AIDS benefits.  The findings reported here serve both as an
indication to government and funding agencies of the contribution of large private sector
employers to national treatment goals and a signal to individual companies about the relative
achievements of their programs.
We found a high average level of access to HIV/AIDS care and treatment, including
antiretroviral therapy, for the entire employee population of the surveyed firms.  This result was
largely driven, however, by the extensive access to benefits at the large mining houses and
financial services firms.  Many companies in other sectors continue to rely solely on medical aid
schemes for which the majority of employees cannot (or choose not to) afford the premiums.
Although all employees at these companies do have access to medical aid coverage, wages are
not high enough to make it a viable option.  We therefore regard the employees of these
companies who are not covered by medical aid as not having access to AIDS treatment.
Based on estimates of HIV prevalence and service utilization supplied by the individual
companies, we find the overall enrolment levels of HIV-positive employees into companies’
treatment programs to be low.  We estimate that fewer than a third of those with HIV are aware
of their own status and enrolled onto an HIV disease management program, while approximately
4 percent of HIV-positive employees—0.6 percent overall—are currently on ART.  Assuming
that an average of 15 percent of employees are HIV-positive, as indicated in Table 5, and at least
10 percent of HIV-positive South Africans are medically eligible for ART, far fewer employees
are accessing treatment than currently need the therapy (Dorrington et al. 2004).  If we
extrapolate the reported uptake rates to all 52 large employers, the result is an estimated 8,000
patients on ART.  While this clearly underestimates the total number of private sector employees
on employer-sponsored ART, as it excludes the very large employers who refused to participate
and the many large and medium-sized companies in which some employees are on ART, the true
number is certainly far smaller than the estimated 30,000 patients who were being treated with
antiretrovirals in the public sector at the time of the survey (Irin 2005).3
Program monitoring, access to care and treatment, and uptake of benefits seem to be related to
the model of service delivery and financing in use.  Few companies relying on medical aid
schemes to deliver treatment and care (Model 2), for example, were able to report uptake figures.
The reason given by many companies was that the medical scheme administrators do not or will
not report utilization rates, even though the companies typically subsidise 50 percent of the
medical aid scheme premiums.  Companies using Model 1 (employer DMP) or Model 3
                                                      
3 The Treatment Action Campaign estimated that ART patient numbers at public sector clinics had risen to 45,000
by June 2005.  TAC also estimated that 50,000-60,000 patients were receiving ART from private for-profit and
nonprofit providers, of which the private sector employer programs described in this paper are one component (TAC
and ALP 2005).
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(independent DMP) were more likely to make ART available to all their employees and reported
higher uptake of services than companies relying exclusively on medical schemes.
We did not explore the reasons for the observed low uptake of benefits and differences in uptake
rates among companies.  The greater uptake reported by companies with employer or
independent DMPs likely reflects better uptake of VCT, which in turn results from active VCT
campaigns by the employers and their DMPs.  We assume that overall low uptake of treatment
services is caused by stigma surrounding HIV/AIDS, lack of trust among employees that their
employer will not learn their status, and the newness of many programs. The commitment of
companies and managers implementing the programs, approaches to recruiting employees into
them, and the quality of the programs themselves need to be examined.
Each of the models for employer-sponsored HIV/AIDS disease management has limitations.  In-
house programs (employer DMPs) may not be feasible if health care is not already provided to
all employees.  Very few companies have the resources or expertise necessary to run an in-house
program.  There are only a handful of independent DMPs operating in South Africa, and quality
seems to vary widely.  Since most companies already offer medical aid coverage, making it
affordable and compulsory for all employees may be the simplest way to extend access to ART.
As noted above, however, medical aid schemes have been the least successful in promoting
uptake of services.
One innovative approach to extending access to ART through a public-private partnership was
reported by an agricultural company and a company in the community/social/personal services
sector.  These companies provide some of the support services necessary for ART, such as
screening and counseling, but rely on government facilities for physicians, laboratory tests, and
antiretroviral medications.  While this model is dependent on having a nearby public treatment
facility, it may prove more feasible and affordable for some employers than the existing models.
The study had several limitations.  First, 12 of the 64 companies in our study population refused
to participate.   The companies that did not participate are distributed across most industrial
sectors (retail, manufacturing, construction, agriculture, energy, and CSPS).  From information
reported by the media, at least 5 of the non-participating companies have active treatment and
care programs in place.  A second limitation is the source of the data:  uptake figures were
reported by company representatives and could not be verified.  Finally, for five companies,
information was provided for only one operating unit.
We conclude that publicity by large employers about their treatment programs should be
interpreted cautiously. The notion that business will play a significant role in meeting national
and international treatment goals is uncertain.  The extent of the current private sector
contribution to national treatment goals is less than the limited media coverage might lead us to
believe.  At this point, it appears that even some of South Africa’s largest employers will wait for
the national public treatment program to assume responsibility for employees sick with AIDS.
The study team noted a good deal of confusion, however, regarding government provision of
ART, options for making ART available to employees, and other policy questions.  Clarifying
these issues for employers may encourage more, and more effective, employer-sponsored
programs.
Treatment of HIV/AIDS at South Africa's largest employers HDDP 5
11
Acknowledgements
Funding for this study was provided by the South Africa Mission of the U.S. Agency for
International Development through its Cooperative Agreement No. 674-A-00-02-00018 with
Right to Care.  We thank our research assistants, Kay Muller and Jeremy Ogusky, who
conducted many of the interviews reported here.
References
Bolin L. “SA firms lead the way on HIV-AIDS.” Sunday Times, 2 June 2005. Available at
http://www.suntimes.co.za/zones/sundaytimesNEW/business/business1117717692.aspx.
Accessed 3 June 2005.
Brink B.  An interim appraisal of the Anglo American AIDS treatment program.  Plenary
presentation at the 2nd South African AIDS Conference, Durban, South Africa, June 10, 2005.
Connelly P, Rosen S. Can small and medium enterprises in South Africa provide HIV/AIDS
services to their employees? A market analysis. CIHD Project Report, March 2004.  Available
at: http://www.bu.edu/dbin/sph/research_centers/cih_impact_hiv.php.  Accessed 25 May 2005.
Dorrington RE, Bradshaw D, Johnson L, Budlender D.  The demographic impact of HIV/AIDS
in South Africa. National indicators for 2004. Cape Town: Centre for Actuarial Research, South
African Medical Research Council and Actuarial Society of South Africa. 2004.
Ellis L, Terwin J. The impact of HIV/AIDS on selected business sectors in South Africa 2004.
Stellenbosch: Bureau for Economic Research, University of Stellenbosch, 2004.
Irin.  South Africa:  capacity shortfalls undermine roll-out.”  Irin PlusNews, 3 March, 2005.
Available from http://www.irinnews.org/pnprint.asp?reportid=4546.  Accessed on 4 March 2005.
Kahn T.  Anglo workers slow to accept offer of free AIDS drugs. Business Day, 17 Feb 2005.
Available at http://www.businessday.co.za/Articles/TarkArticle.aspx?ID=1377835. Accessed 25
May 2005.
Planting S. Champions of the AIDS cause. Financial Mail, 5 September 2003. Available at
http://free.financialmail.co.za/innovations/0905/iinn.htm  Accessed 6 June 2005.
Rosen S, Sanne I, Collier A, Simon J.  Rationing antiretroviral therapy for HIV/AIDS in Africa:
choices and consequences.  PLoS Medicine; in press.
TAC and ALP.  ‘Let them eat cake’—a short assessment of provision of treatment and care 18
months after the adoption of the operational plan.  Second joint report on the implementation of
the Operational Plan for Comprehensive HIV and AIDS Care, Management and Treatment for
South Africa.  Treatment Action Campaign and AIDS Law Project, 8 June 2005.  Available at
http://www.tac.org.za.  Accessed June 13, 2005.
Venter L. Firms fill antiretroviral gap in South Africa. Lancet 2005; 365: 1215–16.
